Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Yutong Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6604-9315; OpenAlex author ID A5039380491. Sources: OpenAlex.

Their work

Papers
15
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2022: 1 paper · 2023: 4 papers · 2024: 4 papers · 2025: 5 papers · 2026: 1 paper

Papers 15

  1. IRP1/ARID3A complex promotes pancreatic cancer chemoresistance by suppressing CYGB-related ferroptosis. Co-author DOI 10.1016/j.gendis.2025.101866↗
  2. Lymphatic metastasis in pancreatic cancer: from bedside to bench and back. Co-author DOI 10.1007/s10555-025-10297-9↗
  3. Nuclear localization of YAP in pancreatic cancer: More players besides Hippo pathway. Co-author DOI 10.1016/j.canlet.2025.217864↗
  4. Phthalocyanine and photodynamic therapy relieve albumin paclitaxel and gemcitabine chemoresistance in pancreatic cancer. Co-author DOI 10.1016/j.yexcr.2025.114455↗
  5. EDC4 enhances multi-drug chemosensitivity in pancreatic cancer via GR50-based profiling. Co-author DOI 10.1186/s12935-025-04000-9↗
  6. Extracellular vesicles-miR-205-5p inhibits lymphatic metastasis in pancreatic cancer through diffusely downregulating VEGFA. Co-author DOI 10.7150/jca.110659↗
  7. Extracellular vesicles miR-31-5p promotes pancreatic cancer chemoresistance via regulating LATS2-Hippo pathway and promoting SPARC secretion from pancreatic st… Co-author DOI 10.1002/jev2.12488↗
  8. Pancreatic ductal adenocarcinoma cells reshape the immune microenvironment: Molecular mechanisms and therapeutic targets. Co-author DOI 10.1016/j.bbcan.2024.189183↗
  9. Circulating tumor cells in pancreatic cancer: more than liquid biopsy. Co-author DOI 10.1177/17588359241284935↗
  10. The systematic role of pancreatic cancer exosomes: distant communication, liquid biopsy and future therapy. Co-author DOI 10.1186/s12935-024-03456-5↗
  11. STOML2 restricts mitophagy and increases chemosensitivity in pancreatic cancer through stabilizing PARL-induced PINK1 degradation. Co-author DOI 10.1038/s41419-023-05711-5↗
  12. EGR1 induces EMT in pancreatic cancer via a P300/SNAI2 pathway. Co-author DOI 10.1186/s12967-023-04043-4↗
  13. Pancreatic cancer stemness: dynamic status in malignant progression. Co-author DOI 10.1186/s13046-023-02693-2↗
  14. DHX38 restricts chemoresistance by regulating the alternative pre-mRNA splicing of RELL2 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pgen.1010847↗
  15. CHRNB2 represses pancreatic cancer migration and invasion via inhibiting β-catenin pathway. Co-author DOI 10.1186/s12935-022-02768-8↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bangbo Zhao · 15 shared papers, 2022–2026 · strength 3.43
  2. Zeru Li · 15 shared papers, 2022–2026 · strength 3.43
  3. Cheng Yong Qin · 8 shared papers, 2024–2026 · strength 2.02
  4. Weibin Wang · 8 shared papers, 2022–2025 · strength 1.80
  5. Tianyu Li · 7 shared papers, 2024–2026 · strength 1.75
  6. Weibin Wang · 7 shared papers, 2023–2026 · strength 1.63
  7. Tianyu Li · 7 shared papers, 2022–2024 · strength 1.41
  8. Cheng‐Feng Qin · 5 shared papers, 2022–2024 · strength 0.99
  9. Yuanyang Wang · 5 shared papers, 2022–2023 · strength 0.94
  10. Haoyu Shi · 3 shared papers, 2025–2026 · strength 0.78
  11. Yiping Xie · 3 shared papers, 2025–2026 · strength 0.75
  12. Xiaoying Yang · 4 shared papers, 2022–2023 · strength 0.74
  13. Cheng Qin · 2 shared papers, 2023–2024 · strength 0.42
  14. Yuanyang Wang · 1 shared paper, 2025 · strength 0.27
  15. Lin Chen · 1 shared paper, 2024 · strength 0.23
  16. Yupei Zhao · 1 shared paper, 2024 · strength 0.23
  17. Tianhao Li · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.